Chemo Pharma Laboratories Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 12.8 Cr.
- Current Price ₹ 85.2
- High / Low ₹ 87.0 / 27.2
- Stock P/E 9.47
- Book Value ₹ 82.8
- Dividend Yield 0.00 %
- ROCE 0.78 %
- ROE 0.43 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.00 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 27.9%
- Company has a low return on equity of 2.02% over last 3 years.
- Earnings include an other income of Rs.1.49 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.14 | 0.09 | 0.13 | 0.12 | 0.17 | 0.27 | 0.34 | 0.56 | 0.48 | 0.34 | 0.41 | 0.20 | 0.11 | |
Operating Profit | -0.14 | -0.09 | -0.13 | -0.12 | -0.17 | -0.27 | -0.34 | -0.56 | -0.48 | -0.34 | -0.41 | -0.20 | -0.11 |
OPM % | |||||||||||||
1.08 | 0.27 | 0.44 | 0.50 | 0.49 | 5.61 | 1.11 | 0.82 | 1.00 | 0.67 | 0.79 | 0.30 | 1.49 | |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.01 | 0.00 |
Profit before tax | 0.93 | 0.17 | 0.31 | 0.38 | 0.32 | 5.34 | 0.77 | 0.26 | 0.50 | 0.31 | 0.36 | 0.08 | 1.38 |
Tax % | 8.60% | 23.53% | 19.35% | 26.32% | 31.25% | 12.17% | 85.71% | 19.23% | 16.00% | 19.35% | -55.56% | 37.50% | |
0.85 | 0.14 | 0.24 | 0.28 | 0.22 | 4.68 | 0.10 | 0.21 | 0.42 | 0.25 | 0.56 | 0.05 | 1.35 | |
EPS in Rs | 5.67 | 0.93 | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.99 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | -10% |
5 Years: | -13% |
3 Years: | -51% |
TTM: | 309% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 55% |
3 Years: | 43% |
1 Year: | 115% |
Return on Equity | |
---|---|
10 Years: | 3% |
5 Years: | 2% |
3 Years: | 2% |
Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
Reserves | 2.97 | 3.11 | 3.35 | 3.62 | 3.84 | 8.52 | 8.62 | 8.83 | 9.24 | 9.49 | 10.05 | 10.10 | 10.92 |
0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
0.22 | 0.27 | 0.35 | 0.46 | 0.20 | 0.58 | 0.13 | 0.09 | 0.22 | 0.06 | 0.11 | 0.02 | 0.01 | |
Total Liabilities | 4.81 | 4.88 | 5.20 | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 12.43 |
0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 1.68 | 1.68 | 1.68 | 1.68 | 1.68 | 0.02 | 0.02 | 0.04 | 0.02 | 0.04 | 2.94 | 3.03 | 3.61 |
3.11 | 3.18 | 3.51 | 3.90 | 3.86 | 10.69 | 10.23 | 10.38 | 10.87 | 10.96 | 8.68 | 8.56 | 8.80 | |
Total Assets | 4.81 | 4.88 | 5.20 | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 12.43 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1.48 | -0.39 | -0.16 | -0.05 | -0.43 | 6.41 | -1.66 | -5.48 | 4.83 | -0.41 | -0.33 | -0.68 | |
2.27 | 0.22 | 0.13 | 0.25 | 0.49 | 0.52 | 1.08 | 0.79 | 1.01 | -0.19 | 0.97 | 0.63 | |
-0.43 | 0.00 | 0.00 | 0.00 | 0.00 | -0.50 | 1.37 | 0.00 | 0.00 | 1.96 | -2.12 | -0.08 | |
Net Cash Flow | 0.36 | -0.17 | -0.03 | 0.20 | 0.06 | 6.43 | 0.79 | -4.70 | 5.84 | 1.36 | -1.49 | -0.13 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | ||||||||||||
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | ||||||||||||
Working Capital Days | ||||||||||||
ROCE % | -2.78% | 3.70% | 6.55% | 7.62% | 6.12% | 3.62% | 7.60% | 2.54% | 4.75% | 2.85% | 1.33% | 0.78% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2d
- Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended March 31, 2024 11 Apr
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
5 Apr - Non-Applicability of Annual Secretarial Compliance Report for the year ended March 31, 2024, under Regulation 24A of SEBI (LODR)Regulations, 2015.
- Compliance Certificate Pursuant To Regulation 7(3) Of Securities Exchange Board Of India (LODR) Regulations, 2015 For The Financial Year Ended 31St March 2024 5 Apr
-
Declaration Of Non-Applicability Of Regulation 23(9) Of SEBI (LODR) Regulation, 2015
2 Apr - Declaration of Non-applicability of Regulation 23(9) of SEBI (LODR) Regulations, 2015 for the half year ended March 31, 2024.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2008
from bse
Background[1]
The Chemo Pharma Laboratories Limited was established in 1942 and has been making pharmaceuticals and diversified into bulk drugs. However due to increase in competition and flow of new drugs, Company disposes their business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals.